Celcuity Inc.

Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for solid tumors. Its primary objective is to address dysregulated oncogenic signaling by inhibiting pathways that drive tumor growth and resistance. The company’s lead therapeutic candidate, gedatolisib, is a potent pan-PI3K and mTORC1/2 inhibitor designed to comprehensively block the PI3K/AKT/mTOR pathway, a central node in cancer proliferation and survival. Celcuity is advancing multiple late-stage studies, including Phase 3 programs in hormone receptor–positive, HER2-negative advanced breast cancer and additional trials exploring combinations across tumor types. The firm’s platform aims to identify previously undetectable cancer drivers, aligning drug development with tumor biology to improve therapeutic precision. Within the biopharmaceutical market, Celcuity contributes to the growing field of pathway-centric oncology, where rational combinations and biomarker-informed strategies seek to enhance clinical benefit and address unmet needs in metastatic settings. This focus positions the company as a participant in the evolution of precision oncology, emphasizing mechanism-driven development and rigorous clinical evaluation.